Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer

Journal of Clinical Oncology

Volumn 32, Issue 34, 2014, Pages 3824-3830

  Iyengar, Puneeth ^a   Kavanagh, Brian D ^b   Wardak, Zabi ^a   Smith, Irma ^a   Ahn, Chul ^a   Gerber, David E ^a   Dowell, Jonathan ^a   Hughes, Randall ^a   Abdulrahman, Ramzi ^a   Camidge, D Ross ^b   Gaspar, Laurie E ^b   Doebele, Robert C ^b   Bunn, Paul A ^b   Choy, Hak ^a   Timmerman, Robert ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN DERIVATIVE; DOCETAXEL; ERLOTINIB; PEMETREXED; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; BACKACHE; CANCER GRADING; CANCER GROWTH; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COMPRESSION FRACTURE; CYTOREDUCTIVE SURGERY; DIARRHEA; DRUG TREATMENT FAILURE; EARLY INTERVENTION; EXON; FATIGUE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HYPOXIA; IATROGENIC DISEASE; LUNG FUNCTION; LUNG FUNCTION TEST; LUNG PARENCHYMA; MALE; METASTATIC NON SMALL CELL LUNG CANCER; MULTIMODALITY CANCER THERAPY; NON SMALL CELL LUNG CANCER; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; RADIATION DOSE FRACTIONATION; RADIATION FIELD; RADIATION INJURY; RADIATION PNEUMONIA; RASH; STEREOTACTIC BODY RADIATION THERAPY; SYSTEMIC THERAPY; TOXICITY; ADJUVANT CHEMOTHERAPY; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CARCINOMA, NON-SMALL-CELL LUNG; CLINICAL TRIAL; DISEASE COURSE; DISEASE FREE SURVIVAL; ENZYMOLOGY; KAPLAN MEIER METHOD; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; RADIOSURGERY; RISK FACTOR; SECONDARY; TIME; TREATMENT OUTCOME; UNITED STATES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CHEMOTHERAPY, ADJUVANT; COLORADO; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RADIOSURGERY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK FACTORS; TEXAS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84912066879     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.56.7412     Document Type: Article

References (38)

1. Ramalingam S, Belani C: Systemic chemotherapy for advanced non-small cell lung cancer: Recent advances and future directions. Oncologist. 13:5-13, 2008 (suppl 1)
2. Socinski MA, Evans T, Gettinger S, et al: Treatment of stage IV non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 143:e341S-e368S, 2013 (suppl 5)
3. Brodowicz T, Ciuleanu T, Crawford J, et al: Third CECOG consensus on the systemic treatment of non-small-cell lung cancer. Ann Oncol 23:1223-1229, 2012
4. Siegel R, Ma J, Zou Z, et al: Cancer statistics, 2014. CA Cancer J Clin 64:9-29, 2014
5. Shepherd FA, Rodrigues Pereira J, National Cancer Institute of Canada Clinical Trials Group, et al: Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132, 2005
6. Iyengar P, Timmerman RD: Stereotactic ablative radiotherapy for non-small cell lung cancer: Rationale and outcomes. J Natl Compr Canc Netw 10:1514-1520, 2012
7. Lo SS, Fakiris AJ, Chang EL, et al: Stereotactic body radiation therapy: A novel treatment modality. Nat Rev Clin Oncol 7:44-54, 2010
8. Timmerman R, Paulus R, Galvin J, et al: Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303:1070-1076, 2010
9. Tree AC, Khoo VS, Eeles RA, et al: Stereotactic body radiotherapy for oligometastases. Lancet Oncol 14:e28-e37, 2013
10. Villaruz LC, Kubicek GJ, Socinski MA: Management of non-small cell lung cancer with oligometastasis. Curr Oncol Rep 14:333-341, 2012
11. Kelsey CR, Salama JK: Stereotactic body radiation therapy for treatment of primary and metastatic pulmonary malignancies. Surg Oncol Clin N Am 22:463-481, 2013
12. Salama JK, Kirkpatrick JP, Yin FF: Stereotactic body radiotherapy treatment of extracranial metastases. Nat Rev Clin Oncol 9:654-665, 2012
13. Hasselle MD, Haraf DJ, Rusthoven KE, et al: Hypofractionated image-guided radiation therapy for patients with limited volume metastatic non-small cell lung cancer. J Thorac Oncol 7:376-381, 2012
14. Salama JK, Hasselle MD, Chmura SJ, et al: Stereotactic body radiotherapy for multisite extracranial oligometastases: Final report of a dose escalation trial in patients with 1 to 5 sites of metastatic disease. Cancer 118:2962-2970, 2012
15. Milano MT, Katz AW, Zhang H, et al: Oligometastases treated with stereotactic body radiotherapy: Long-term follow-up of prospective study. Int J Radiat Oncol Biol Phys 83:878-886, 2012
16. Milano MT, Philip A, Okunieff P: Analysis of patients with oligometastases undergoing two or more curative-intent stereotactic radiotherapy courses. Int J Radiat Oncol Biol Phys 73:832-837, 2009
17. Rusthoven KE, Kavanagh BD, Cardenes H, et al: Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. J Clin Oncol 27:1572-1578, 2009
18. Rusthoven KE, Kavanagh BD, Burri SH, et al: Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. J Clin Oncol 27:1579-1584, 2009
19. Weickhardt AJ, Scheier B, Burke JM, et al: Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol 7:1807-1814, 2012
20. Gan GN, Weickhardt AJ, Scheier B, et al: Stereotactic radiation therapy can safely and durably control sites of extra-central nervous system oligoprogressive disease in anaplastic lymphoma kinasepositive lung cancer patients receiving crizotinib. Int J Radiat Oncol Biol Phys 88:892-898, 2014
21. Passaro A, Cortesi E, de Marinis F: Secondline treatment of non-small-cell lung cancer: Chemotherapy or tyrosine kinase inhibitors? Expert Rev Anticancer Ther 11:1587-1597, 2011
22. Tassinari D, Scarpi E, Sartori S, et al: Noninferiority trials in second-line treatments of nonsmall cell lung cancer: A systematic review of literature with meta-analysis of phase III randomized clinical trials. Am J Clin Oncol 35:593-599, 2012
23. Weichselbaum RR, Hellman S: Oligometastases revisited. Nat Rev Clin Oncol 8:378-382, 2011
24. Ashworth A, Rodrigues G, Boldt G, et al: Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer 82:197-203, 2013
25. Badakhshi H, Grün A, Stromberger C, et al: Oligometastases: The new paradigm and options for radiotherapy - A critical review. Strahlenther Onkol 189:357-362, 2013
26. Bradley CT, Strong VE: Surgical management of adrenal metastases. J Surg Oncol 109:31-35, 2014
27. Leo F, Cagini L, Rocmans P, et al: Lung metastases from melanoma: When is surgical treatment warranted? Br J Cancer 83:569-572, 2000
28. Ito K, Govindarajan A, Ito H, et al: Surgical treatment of hepatic colorectal metastasis: Evolving role in the setting of improving systemic therapies and ablative treatments in the 21st century. Cancer J 16:103-110, 2010
29. Petersen RP, Hanish SI, Haney JC, et al: Improved survival with pulmonary metastasectomy: An analysis of 1,720 patients with pulmonary metastatic melanoma. J Thorac Cardiovasc Surg 133:104-110, 2007
30. Rusthoven KE, Hammerman SF, Kavanagh BD, et al: Is there a role for consolidative stereotactic body radiation therapy following first-line systemic therapy for metastatic lung cancer? A patterns-of-failure analysis. Acta Oncol 48:578-583, 2009
31. Simon R, Norton L: The Norton-Simon hypothesis: Designing more effective and less toxic chemotherapeutic regimens. Nat Clin Pract Oncol 3:406-407, 2006
32. Park C, Papiez L, Zhang S, et al: Universal survival curve and single fraction equivalent dose: Useful tools in understanding potency of ablative radiotherapy. Int J Radiat Oncol Biol Phys 70:847-852, 2008
33. Carmichael J, Degraff WG, Gamson J, et al: Radiation sensitivity of human lung cancer cell lines. Eur J Cancer Clin Oncol 25:527-534, 1989
34. Morstyn G, Russo A, Carney DN, et al: Heterogeneity in the radiation survival curves and biochemical properties of human lung cancer cell lines. J Natl Cancer Inst 73:801-807, 1984
35. Hellman S, Weichselbaum RR: Oligometastases. J Clin Oncol 13:8-10, 1995
36. Gerber DE: Maintenance therapy for advanced lung cancer: Who, what, and when? J Clin Oncol 31:2983-2990, 2013
37. Palma DA, Haasbeek CJ, Rodrigues GB, et al: Stereotactic ablative radiotherapy for comprehensive treatment of oligometastatic tumors (SABR-COMET): Study protocol for a randomized phase II trial. BMC Cancer 12:305, 2012
38. Griffioen GH, Toguri D, Dahele M, et al: Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors. Lung Cancer 82:95-102, 2013